Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Take part in our new study looking at flu vaccines

The Oxford Vaccine Group, part of the University of Oxford, would like to invite you and your child to take part in a study to investigate the immune response to a flu vaccine.

We are looking to enroll healthy Caucasian children aged 13 to 24 months, these children would receive two doses of a flu vaccine and three blood tests. Healthy Caucasian adults aged 18 to 65 years are also able to participate, they would receive one dose of a flu vaccine and four blood tests. We would use local anaesthetic cream on the skin to reduce any discomfort from the blood sampling.

You would have 24 hour telephone access to a paediatrician, should you have any concerns following vaccination. Taking part in this study is voluntary.

If you would like to any further information please visit:

Our website

You can also contact us by telephone on 01865 857420 or you can e-mail us at info@ovg.ox.ac.uk.

 

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.